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T helper 2 cytokines, including interleukin (IL)-4, IL-5, and IL-13, play a critical role in 
allergic asthma. These cytokines transmit signals through the Janus kinase/signal transducer 
and activator of transcription (STAT) and the Ras–extracellular signal-regulated kinase 
(ERK) signaling pathways. Although the suppressor of cytokine signaling (SOCS) family 
proteins have been shown to regulate the STAT pathway, the mechanism regulating the ERK 
pathway has not been clarified. The Sprouty-related Ena/VASP homology 1–domain-
containing protein (Spred)-1 has recently been identified as a negative regulator of growth 
factor–mediated, Ras-dependent ERK activation. Here, using Spred-1–deficient mice, we 
demonstrated that Spred-1 negatively regulates allergen-induced airway eosinophilia and 
hyperresponsiveness, without affecting helper T cell differentiation. Biochemical assays 
indicate that Spred-1 suppresses IL-5–dependent cell proliferation and ERK activation. 
These data indicate that Spred-1 negatively controls eosinophil numbers and functions by 
modulating IL-5 signaling in allergic asthma.
 
Asthma is characterized by a variable degree
of airflow obstruction, airway hyperresponsive-
ness (AHR; defined by enhanced airflow ob-
struction in response to nonspecific stimuli),
mucus overproduction, and chronic airway in-
flammation. Numerous eosinophils and lym-
phocytes infiltrate peribronchial tissues in
asthmatics. Th2 cells are the predominant lym-
phocyte population that infiltrates the airways
of asthmatics, and the cytokine products of Th2
cells play essential roles in airway eosinophilia,
AHR, and serum IgE in animal models (1).
Eosinophils are produced in bone marrow, and
recent observations in both mice and humans
suggest that pulmonary allergen exposure results
in both increased output of eosinophils from
hemopoietic tissues and increased migration of
these cells to the lung (2–4). It is the accumu-
lation of activated eosinophils during the late-
phase response to allergen exposure that ulti-
mately results in progressive inflammatory tissue
damage. In addition, pulmonary eosinophilia
in response to allergen challenge is associated
with elevated levels of eosinophil-derived
proteins in both the lungs and peripheral blood
(5, 6). However, the specific mechanisms that
alter eosinophilopoiesis in asthma are poorly
understood.
Eosinophil production is predominantly
regulated by the Th2 cytokine, IL-5 (7, 8). IL-5
receptor consists of IL-5–specific 
 
 
 
-chain and
the common 
 
 
 
-chain that is shared by the IL-3
and GM-CSF receptor (9). In addition to the
JAK–STAT pathway, the Ras–extracellular sig-
nal-regulated kinase (ERK) pathway has also
been implicated in signaling of IL-5 and other
cytokines (10–12), and this pathway is shown
to be important for IL-5–dependent cell
survival (12). Therefore, the Ras-ERK sig-
nals seem to be important for eosinophilia in
asthma; however, the regulation of this path-
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way and its contribution to the disease have not been
clarified.
ERK activation is initiated by binding of Grb2 to the
phosphorylated tyrosine residues of the receptor or phos-
phorylated adaptor molecules such as Shc, FRS-2, IRS-1/2,
SHP-2, and Gab-1. The complex of Grb2 and SOS activates
Ras by GTP loading. Ras-GTP recruits Raf-1 to the plasma
membrane (13, 14). Raf-1 is phosphorylated and activated by
not well-defined kinases with complex regulatory mecha-
nisms (15). Activated Raf phosphorylates and activates the
dual-specific kinase MEK, which phosphorylates and acti-
vates ERK. The regulation of this pathway has been sug-
gested to be quite important for cell proliferation and differ-
entiation. Recently, Sprouty family proteins were identified
as negative regulators for several growth factor-induced ERK
activation including FGF and EGF (9, 16). Four Sprouty ho-
mologues are found in mammals. We cloned an additional
Sprouty-related family of novel membrane bound molecules,
Sprouty-related Ena/VASP homology 1–domain-containing
proteins (Spreds; reference 17). Three members of Spreds
were identified in mammals (18), which have a Sprouty-
related COOH-terminal cysteine-rich domain in addition to
the NH
 
2
 
-terminal Ena/VASP homology 1 domain. Like
Sproutys, Spred-1, Spred-2, and Spred-3 also down-regulate
Ras/ERK signaling. As Spred inhibits active Ras-induced
ERK activation, Spred might modulate the unidentified acti-
vation steps of Raf by a novel mechanism. Spred/Sprouty
family proteins have emerged as a negative regulator of the
ERK pathway; however, details of their physiological func-
tion and molecular mechanism remain to be investigated.
In the present paper, we generated Spred-1 knockout
mice and examined the function of Spred-1 on the develop-
ment of asthma and associated eosinophilia. We show that
Spred-1
 
   
 
 
 
mice exhibited exaggerated allergen-induced
AHR, eosinophilia, and mucus production in a murine aller-
gic asthma model. Spred-1
 
   
 
 mice also showed increased
responsiveness, especially ERK signals, to IL-5 and subse-
quent overexpression of IL-13 in eosinophils. Thus, it is
conceivable that the down-regulation of Spred-1 in the air-
ways has a significant role in prolonged airway eosinophilia
and asthma phenotypes. We propose the possibility that
Spred-1 may present a novel therapeutic target for the treat-
ment of asthma.
 
RESULTS
Generation of Spred-1
 
   
 
 mouse and assessment 
of T cell development
 
We found that Spred-1 is highly expressed in hematopoietic
cells (unpublished data). To examine the function of Spred-1
in Th1/Th2 cell differentiation and diseases, we generated
mice lacking the Spred-1 gene by homologous recombination
techniques (Fig. 1). To obtain the loss-of-function mutant,
exons containing the kit-binding domain and Sprouty-related
COOH-terminal cysteine-rich domains were deleted. Loss of
Spred-1 protein expression was confirmed by Western blot-
ting of the tissue extracts. Spred-1 protein was detected in the
brain of the WT mice but not in that of the mutant mice.
Offspring were born within the Mendelian expectation ratio
from intercrosses of heterozygotes as well as incrosses of ho-
mozygotes. This indicates that Spred-1 is not necessary for
fertility and development. Adult Spred-1
 
   
 
 mice appeared to
be healthy, except that a slight lower body weight, a short-
ened face, and a kinky tail, but they showed no apparent ab-
normalities in most organs (unpublished data). No abnormali-
ties of peripheral hematopoietic cell population and number,
CD4/CD8 profiles of spleen and thymus, or B cell develop-
ment were observed in Spred-1
 
   
 
 mice (unpublished data).
 
Enhanced OVA-induced asthma phenotypes in Spred-1
 
   
 
 mice
 
Because the ERK pathway is shown to be involved in the
Th1/Th2 balance (19–21), we investigated the role of Spred-1
in a Th2-type disease, bronchial asthma, using an OVA-
Figure 1. Generation of Spred-1–deficient mice. (A) Schematic repre-
sentations of wild-type and mutant loci of the Spred-1 gene together with 
the targeting vector. Exons (from the second to fourth) for genes encoding 
Spred-1 are represented by black boxes. The neomycin-resistance gene 
driven by a PGK promoter (pgk-neo) and the gene coding the thymidine 
kinase driven by an HSV promoter (hsv-tk) are indicated by white boxes. 
EcoRV-digested genomic DNA fragments were detected by probe. Restric-
tion sites: E, EcoRI; Ev, EcoRV; H, HindIII; A, ApaI; K, KpnI; X, XhoI. (B) Repre-
sentative Southern blot analysis with HindIII-digested DNA. The positions 
of probes are shown in A. (C) Genomic PCR analysis of tails of indicated 
mice. (D) RT-PCR analysis of Spred-1 and control GAPDH expression in 
total RNA of brains of wild-type and Spred-1    mice. (E) Western blotting 
of brain, liver, and kidney with anti–Spred-1 antibody. C2C12 cells that ex-
press Spred-1 endogenously at high levels are shown as a positive control. 
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induced asthma model. After systemic sensitization to OVA and
aerosolized OVA challenges, airway responsiveness to acetyl-
choline aerosol was measured using an invasive technique
(22). WT mice demonstrated AHR to acetylcholine, and
Spred-1
 
   
 
 mice exhibited significantly enhanced AHR com-
pared with WT mice (Fig. 2, A and B). OVA sensitization
and challenge resulted in an increased number of eosinophils in
bronchoalveolar lavage (BAL) fluid in WT mice. Spred-1
 
   
 
mice after an OVA challenge displayed a further increase in
eosinophils in BAL fluids compared with WT mice, although
there was no significant difference in the number of lympho-
cytes and neutrophils (Fig. 2 C). There was no difference in
OVA-induced asthma between C57BL/6 mice and WT
(Spred-1
 
   
 
) littermates (unpublished data). Alcian blue/peri-
odic acid-Schiff (PAS) staining was performed to examine the
levels of mucus hyperproduction. After OVA challenge, mild
staining in the airways of WT mice cells was noted, and stain-
ing levels were increased significantly in the intrapulmonary
bronchi of Spred-1
 
   
 
 mice (Fig. 2, D and E), indicating en-
hanced goblet cell metaplasia in Spred-1
 
   
 
 lung. In the ab-
sence of sensitization and challenges, no substantial differences
were apparent in ARH to acetylcholine, inflammatory cells in
BAL fluids, and Alcian blue/PAS staining cells in the airways
between Spred-1
 
   
 
 and WT mice.
Next, we directly measured cytokines and eotaxin levels
in mouse BAL fluids. The challenge with OVA increased
the concentrations of IL-13 and eotaxin in Spred-1
 
   
 
 mice
significantly more than in WT mice (Fig. 3 A), reflecting
marked eosinophilia in the airways of Spred-1
 
   
 
 mice.
However, there was no difference in the concentration of
IL-4, IL-5, or IFN-
 
 
 
 in BAL fluids after OVA challenges
between Spred-1
 
   
 
 and WT mice.
 
Th1/Th2 responses in Spred-1
 
   
 
 T cells
 
Enhanced AHR in Spred-1
 
   
 
 mice may be explained by a
simple increased Th2 response, although IL-4 levels were not
altered. Therefore, we measured serum IgE levels that are de-
termined by Th1/Th2 balance. The concentrations of total
IgE and OVA-specific IgE in Spred-1
 
   
 
 mice were similar to
those in WT controls (Fig. 4 A). There were no significant dif-
ferences in serum IgA levels among the groups (Fig. 4 A).
CD4
 
 
 
 T cells were isolated from draining lymph node cells
from paratracheal and mediastinal lymph nodes after OVA
Figure 2. Effects of Spred-1 inactivation on asthmatic responses in 
an OVA-induced asthma model. Mice were sensitized and aerosol chal-
lenged with OVA. Airway responsiveness was determined by the acetylcholine-
dependent change in airway pressure in saline-treated control and OVA-
sensitized/-challenged LM and Spred-1–deficient mice (A) and the calculation 
of PC200 (B). (C) Effects of Spred-1 depletion on cell counts in BAL fluid. 
*, P   0.05 by analysis of variance with Bonferroni correction. 
(D) Semiquantitative analysis of the abundance of PAS-positive mucus-
containing cells. Lung tissue sections were obtained from formalin-fixed, 
paraffin-embedded lung tissue prepared and stained with Alcian blue/PAS. 
PAS-positive cells were defined as the average of the sore as described in 
Materials and Methods. *, P   0.05 by Kruskal-Wallis test with Mann-
Whitney U test. (E) Representative lung tissue sections. Original magnifi-
cation, 200.
Figure 3. Elevated IL-13 levels in BAL fluid of Spred-1–deficient 
mice. (A) Effects of Spred-1 inactivation on cytokine levels in BAL fluid in 
an OVA-induced asthma model. Data are means   SEM of at least six 
mice per group. *, P   0.05 by analysis of variance with Bonferroni correc-
tion. (B) Eosinophils isolated from BAL of OVA-sensitized/-challenged WT 
and Spred-1–deficient mice were incubated at 106 cells/ml for 24 h. The 
secretion of IL-13 from Spred-1–deficient mouse eosinophils was signifi-
cantly higher than that from WT mouse eosinophils (n   6). Data are ex-
pressed as the mean   SEM of six mice. *, P   0.05 by Student’s t test. 
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challenges and stimulated in vitro with anti-TCR plus anti-
CD28 mAbs. IL-4, IL-5, IL-13, and IFN-
 
 
 
 production from
CD4
 
 
 
 T cells was similar between Spred-1
 
   
 
 and WT mice
(Fig. 4 B). These data suggest that Spred-1 does not affect
Th1/Th2 differentiation and cytokine production from T cells.
To confirm these conclusions, we assessed the develop-
ment of Th1 and Th2 cells from naive CD4
 
 
 
 T cells in WT
and Spred-1
 
   
 
 mice. T cells were stimulated with anti-
TCR plus anti-CD28 mAbs, and the population of IL-4– or
IFN-
 
 
 
–producing cells was analyzed by intracellular FACS
staining. The ratio of IL-4– and IFN-
 
 
 
–producing T cells
was comparable between Spred-1
 
   
 
 and WT mice. IL-4
and IFN-
 
 
 
 levels in the culture supernatant were also com-
parable (unpublished data). We also tested the generation of
Th1 and Th2 cells under a Th1- or Th2-skewed condition.
Naive CD4
 
 
 
 T cells were stimulated with anti-TCR mAb
in the presence of IL-4 plus anti–IL-12 mAb or of IL-12 plus
anti–IL-4 mAb. There were no significant differences in the
generation of IL-4–dependent Th2 cells or IL-12–dependent
Th1 cells between Spred-1
 
   
 
 and WT T cells (Fig. 4 C).
These data suggested that the development of asthma pheno-
types is enhanced in Spred-1
 
   
 
 mice through the up-regu-
Figure 4. Intact Th1/Th2 response in Spred-1–deficient mice. (A) Serum 
concentration of total IgE, OVA-specific IgE, and total IgA in an OVA-induced 
asthma model. Data are means   SEM of at least six mice per group. 
(B) Cytokine production from CD4  T cells after stimulation with anti-TCR 
plus anti-CD28 mAbs. CD4  T cells were isolated from paratracheal and 
mediastinal lymph node cells from WT and Spred-1–deficient mice after 
OVA challenges and cultured with anti-TCR plus anti-CD28 mAbs in vitro 
for 48 h. Cytokine production in the supernatants was assessed by ELISA. 
All data are means   SEM. (C) CD4  T cells from WT and Spred-1–deficient 
mice were stimulated for 5 d with anti-TCR plus anti-CD28 mAbs in the 
presence of IL-12 and anti–IL-4 mAb (Th1-skewed condition) or IL-4 and 
anti–IL-12 mAb (Th2-skewed condition). The generation of Th1 and Th2 
cells was assessed by cytoplasmic staining with IL-4 and IFN- . The abso-
lute numbers of cells harvested were similar in these cultures. The per-
centages of cells in each quadrant are shown. Three independent experi-
ments were performed with similar results. 
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lation of a limited repertoire of Th2 cytokines, such as IL-
13, and that this is not due to the enhancement of antigen-
specific Th2 immune responses.
In addition to T cells, eosinophils produce Th1 and Th2
cytokines, including IL-5 and IL-13 (23, 24). Next, we in-
vestigated IL-13 expression in accumulated eosinophils in
the airways of OVA-challenged mice (Fig. 3 B). Eosinophils
were isolated from BAL fluids and incubated in vitro for the
evaluation of IL-13 production. Airway eosinophils isolated
from Spred-1
 
   
 
 mice secreted significantly higher levels of
IL-13 than those from WT mice (Fig. 3 B). These findings
indicate that the IL-13 production from eosinophils is aug-
mented in Spred-1
 
   
 
 mice.
 
Increased eosinophilia in response to IL-5 but not to IL-13 
in Spred-1
 
 
 
/
 
 
 
 mice
 
It has been shown that IL-5 is critical for the induction of
eosinophilia (25–27), as is IL-13 for the development of
eosinophilic inflammation and AHR (28, 29). Thus, to elu-
cidate the mechanism of enhanced OVA-induced asthma
phenotypes and preferential IL-13 production in Spred-1
 
   
 
mice, we analyzed the response of eosinophils to these cyto-
kines. Intratracheal administration of recombinant mouse IL-
13 increased eosinophil counts in BAL fluids in WT mice;
however, the level of eosinophilia after IL-13 instillation
in Spred-1
 
   
 
 mice was comparable to that in WT mice
(unpublished data). Intraperitoneal injection of recombinant
mouse IL-5 into WT mice induced an increase in the eo-
sinophil number in peripheral blood as reported previously
(30). In Spred-1
 
   
 
 mice, IL-5 injection induced a promi-
nent and prolonged increase in peripheral eosinophil counts
(Fig. 5 A).
To confirm the hyperresponsiveness of Spred-1
 
   
 
 eosin-
ophil progenitors to IL-5 in vitro, IL-5–dependent colonies
were counted from the bone marrow and spleen of Spred-
1
 
   
 
 and WT mice. Bone marrow and splenic cells were
cultured with IL-5 as the only supportive cytokine to enu-
merate eosinophil precursors. In this medium, the number of
colonies from Spred-1–deficient bone marrow and splenic
cells was more than those from WT cells (Fig. 5 B). These
data suggest that Spred-1
 
   
 
 mice contain more eosinophil
progenitors than WT mice or that the hematopoietic pro-
genitors of Spred-1
 
   
 
 mice are more sensitive to IL-5.
Because the Ras–ERK pathway has been shown to regu-
late eosinophil chemotaxis (31), we performed the chemotaxis
experiment with eosinophils derived from bone marrow of
Spred-1
 
   
 
 or WT mice. Chemotaxis of eosinophils from
Spred-1
 
   
 
 mice was accelerated in response to eotaxin com-
pared with WT mice (Fig. 5 C). These findings indicate that
Spred-1
 
   
 
 mice exhibit the hyperresponsiveness of eosinophil
to IL-5 and to eotaxin and enhanced/sustained eosinophilia.
 
Spred-1 inhibits IL-5–mediated ERK activation 
and cell proliferation
 
IL-5 activates the propagation of signals principally via
the JAK–STAT pathways, especially STAT5, and the Ras-
MAPK pathways (32). To elucidate the molecular mecha-
nism by which the inactivation of Spred-1 enhances IL-5
responses, we analyzed the JAK-STAT and Ras–MAPK path-
ways using an IL-5–dependent cell line, Y16 (33). Al-
though forced expression of WT or 
 
 
 
C-Spred-1 did not af-
fect IL-5–induced JAK2 and STAT5 activation, WT Spred-1
reduced Raf-1 and ERK activation, and the dominant nega-
tive 
 
 
 
C mutant of Spred-1 augmented Raf-1 and ERK acti-
vation (Fig. 6 A).
Other tyrosine kinases such as Lyn and JAK2 have been
shown to enhance eosinophil differentiation (34). Therefore,
we analyzed the interaction of Spred-1 with Raf-1, Lyn, and
JAK2 kinases in Y16 cells transfected with WT Flag-Spred-1.
The expression levels of Lyn in Y6 cells was very low, so we
could not conclude the interaction between Lyn and Spred-1.
Raf-1 was coimmunoprecipitated with Spred-1 as reported
previously (17). However, JAK2 was not coimmunoprecipi-
tated with Spred-1 (Fig. 6 B). These data further support our
Figure 5. Eosinophil response to IL-5 or to eotaxin and IL-13 produc-
tion from isolated eosinophils. (A) Recombinant mouse IL-5 (10,000 U/d) 
was injected intraperitoneally into WT or Spred-1–deficient mice for 4 d. 
Differential counts were performed by examination of blood smear stained 
with a modified Wright-Giemsa stain at various time points (left). Typical 
appearances of blood smear from WT and Spred-1–deficient mice at day 7 
are shown (right). Original magnification, 400. *, P   0.05 and **, P   0.01 
by Student’s t test. (B) Colony formation of eosinophil progenitors in bone 
marrow and splenic cells. Bone marrow or splenic cells were plated in meth-
ylcellulose containing 10 ng/ml IL-5. On day 14, the number of colonies was 
counted microscopically. (C) Eotaxin-induced eosinophil chemotaxis. Eosin-
ophils from bone marrow of WT or Spred-1–deficinet mice were allowed to 
migrate to 100 ng/ml eotaxin through polycarbonate filter for 60 min. The 
migrated cells were counted. Data are reported as migration index and they 
are calculated as follows: (number of cells migrating to chemoattractant)/
(number of cells migrating to vehicle). Data are means   SEM of six experi-
ments. * P   0.05 by Mann-Whitney U test. 
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proposal that the effect of Spred-1 is specific to the down-
stream of JAK2 (i.e., the Ras–Raf–ERK pathway).
Next, we examined the effect of WT and 
 
 
 
C-Spred-1
on IL-5–dependent proliferation of Y16 cells. WT and 
 
 
 
C-
Spred-1 cDNAs were introduced into Y16 cells with en-
hanced GFP (EGFP) using a bicistronic retrovirus vector
pMY-IRES-EGFP (35). Because the infected cells expressed
both EGFP and Myc-tagged Spred-1, the percentage of in-
fected cells was determined as the EGFP-positive rate by
flow cytometry. When Y16 cells were cultured in a medium
containing 5 U/ml IL-5 for 4 wk, the proportion of control
IRES-EGFP–infected cells was unchanged; however, the
population of WT Spred-1–infected cells decreased, whereas
that of 
 
 
 
C-Spred-1–infected cells increased (Fig. 6 C). The
MEK inhibitor, U0126, blocked IL-5–induced proliferation
of 
 
 
 
C-Spred-1–transfected Y16 cells as efficiently as parental
Y16 cells (Fig. 6 D). These results suggest that the inactiva-
tion of Spred-1 enhances IL-5 responses through augment-
ing Ras–MAPK activity.
To further confirm the effect of Spred-1 on IL-5–depen-
dent signals in more physiological conditions, BM–derived
eosinophil (BMEo) cells were analyzed (Fig. 7). Activations
of Raf-1 and ERK2 were augmented in Spred-1
 
   
 
 BMEos
compared with WT BMEos, but JAK2 activation was not
affected (Fig. 7). These results further supported that Spred-1
inhibits the Ras–ERK pathway downstream of IL-5/JAK2
and that the hyperresponsiveness of Spred-1
 
   
 
 eosinophils
to IL-5 may be explained by enhanced ERK activation.
 
DISCUSSION
 
We have recently identified Spreds and determined that
Spred-1 interacts with Ras and inhibits growth factor–
induced Raf kinase activation (17). The present paper dem-
onstrated that Spred-1 inactivation by a dominant negative
mutant enhances IL-5 signals via the Ras–MAPK path-
way and IL-5–induced cell proliferation, whereas Spred-1
overexpression suppresses IL-5–induced Ras–MAPK activ-
ity. Spred-1–deficient mice exhibit augmented eosinophilia
Figure 6. Effect of WT and  C Spred-1 on IL-5–induced ERK acti-
vation and proliferation of Y16 cells. (A) Y16 cells transfected with 
Flag-tagged WT or  C Spred-1 were stimulated with 50 U/ml IL-5 for in-
dicated periods. Cell extracts were immunoblotted with the indicated anti-
bodies. (B) Interaction of Spred-1 with Raf1, Lyn, and JAK2. Y16 cells were 
transfected with WT Flag-Spred-1. Anti-Flag immunoprecipitates (IP) from 
Y16 cells with or without incubation of 50 U/ml IL-5 were blotted (IB) with 
the indicated antibodies. TCL, total cell lysates. (C) Retroviruses carrying 
Flag-tagged WT and COOH-terminal–truncated Spred-1 ( C-Spred-1). 
cDNAs in pMY-IRES-GFP vector were produced by transfection of the 
PLAT-E packaging cell line. Y16 cells were infected with viruses for 24 h in 
the presence of 5 U/ml IL-5. The changes of the proportion of GFP-positive 
cells with 5 U/ml IL-5 for indicated periods were assayed by flow cytometer. 
(D) Effect of MEK inhibitor, U0126, on IL-5–induced proliferation. Y16 cells 
transfected with WT or  C Spred-1 were preincubated with buffer, vehicle 
DMSO, or U0126 for 30 min and cultured with 50 U/ml IL-5 for 48 h. Cell 
proliferation was measured by colorimetric assay using WST-8 and 
1-methoxy PMS.JEM VOL. 201, January 3, 2005 79
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in response to IL-5. It has been suggested that the Ras–MAPK
pathway might regulate Th cell development (19–21, 36).
By using mouse models, we demonstrated that Spred-1 inac-
tivation increases allergen-induced expression of IL-13 and
magnifies asthma phenotypes without affecting Th2 differ-
entiation including IL-4 or IgE levels. We further demon-
strated that IL-13 production by airway eosinophils is up-
regulated in Spred-1–deficient mice after allergen challenges.
IL-5 (25–27) and IL-13 (28, 29) are critical for the develop-
ment of asthma. Therefore, these data suggest that Spred-1
plays an important regulatory role in asthma by modulating
the signaling of a limited repertoire of Th2 cytokines.
IL-4 has been suggested to be important for the genera-
tion of allergen-specific Th2 cells during sensitization (37),
and the roles of Ras–MAPK activation in IL-4 production
and Th2 differentiation have been investigated. Although
some reported no effect on IL-4 production in T cells when
inhibiting ERK activity (37), others report a decrease (19,
38) or increase in IL-4 expression and subsequent Th2 dif-
ferentiation (20, 21). In the present paper, we showed that
IL-4 and IFN-  production in vitro from Th cells in re-
sponse to anti-TCR from Spred-1–deficient mice is normal.
Furthermore, the levels of IL-4 in the airways and serum IgE
after allergen challenge in vivo in Spred-1–deficient mice
were comparable to those in WT mice. Thus, we consider
that Spred-1 may not influence Th2 differentiation.
The higher numbers of IL-5–dependent colonies from the
bone marrow and spleen from Spred-1    mice than those
from WT mice suggest that Spred-1–deficient mice contain
an increased number of eosinophil progenitors. The mecha-
nism for this is not clear at present. Our paper shows that
Spred-1 inactivation by a dominant negative mutant enhances
IL-5 signals via the Ras–MAPK pathway and IL-5–induced
cell proliferation using the IL-5–dependent murine B cell line,
Y16. Therefore, Spred-deficient eosinophil progenitor cells
may respond more efficiently to IL-5. However, we could not
rule out the possibility that Spred-1–deficient mice contain a
higher number of stem cells, which respond better to the stem
cell factor. Allergen-induced eosinophilia is probably due to a
higher response of progenitors to IL-5. IL-5 activates several
kinases, including Btk, JAK2, Lyn, and Raf-1, as well as the
phosphatase SHP2 (32, 39, 40). In eosinophils, JAK2 and Lyn
appear to be important for cell proliferation and survival,
whereas Raf-1 seems to play a central role in regulating cell
function, such as degranulation, adhesion, and survival (41).
Because IL-5–induced eosinophilia is markedly enhanced and
prolonged in Spred-1–deficient mice, Spred-1 might affect
eosinophil proliferation and/or survival in response to IL-5.
Our present data suggest that Spred-1 regulates IL-13 ex-
pression through the inactivation of Ras–MAPK signals.
This hypothesis is supported by the previous findings that
eosinophils have the potential to produce IL-13 (24, 42) and
that the Ras–ERK pathway mediates induction of IL-13 ex-
pression in T cells (43) and mast cells (44). The downstream
functional target molecules of Ras–MAPK in IL-13 induc-
tion in response to IL-5 have not been clarified. It has been
reported that the IL-5 receptor expression on airway eosino-
phils is down-regulated after an inhaled allergen challenge
and that this is associated with a loss of IL-5 responsiveness
(45, 46). However, it is unlikely that Spred-1 modulates IL-5
receptor expression because a specific inhibitor of MAPK ki-
nase (MEK) 1 had no effect on the down-regulation of IL-5
receptor  -chain in eosinophils (47).
We demonstrated that the IL-5–mediated proliferation
of Y16 cells is inhibited by WT Spred-1 transfection,
whereas it is increased by  C-Spred-1 in the present paper.
Furthermore, a MEK inhibitor, U0126, blocked IL-5–
induced proliferation in Y16 cells, and the inhibitory effect
of U0126 was similar between parental Y16 cells and  C-
Spred-1 transfectants. These data suggest that Spred-1 regu-
lates IL-5–dependent proliferation by modulating the ERK
pathway. It has already been demonstrated that pharmaco-
logical inhibitor of ERK phosphorylation attenuates aller-
gen-induced airway reactions (48). Our findings and the
previous paper suggest that the Ras–ERK pathway is critical
in the development of eosinophilic inflammation and AHR.
Given the variety of cellular distribution of Spred-1 ex-
pression including airway epithelial cells, endothelial cells
(49), hematopoietic progenitor cells (unpublished data), and
eosinophils in the present paper, it is unlikely that all of the
asthma phenotypes in Spred-1    mice are due to Spred-1
deficiency on eosinophils. In addition, other Spred family
members might also regulate eosinophilia and allergen-
induced AHR. However, our data clearly demonstrate that
Spred-1    mice showed prominent airway eosinophilia and
intact Th1/Th2 differentiation, and Spred-1    eosinophils
are more sensitive to IL-5–induced proliferation and Raf-1/
ERK activation, as well as eotaxin-induced migration in
vitro. Therefore, it is possible that hyperresponsive eosino-
phils to IL-5 and eotaxin in Spred-1    mice may predomi-
nantly contribute to the airway pathology in these mice.
Our studies provide evidence that Spred-1 is critical for
the IL-5 response and IL-13 production and for allergen-
Figure 7. The activation of Raf-1, ERK2, and JAK2 in IL-5–stimulated 
eosinophils from Spred-1    and WT mice. Eosinophils derived from 
bone marrow were stimulated with 1,500 U/ml IL-5 for indicated periods. 
Cell extracts were immunoblotted with the indicated antibodies.SPRED-1 NEGATIVELY REGULATES IL-5 RESPONSES | Inoue et al. 80
induced asthma without influencing Th2 development. Al-
though the relationship between total IgE and asthma preva-
lence is well known (50), an atopic status is not an associated
finding in severe asthma (51). There is considerable evidence
to support a critical role for the involvement of Th2 cyto-
kines and eosinophils both in atopic and in nonatopic
asthma. In particular, IL-5 is critical for eosinophilia, and IL-
13 has the potential to modulate airway inflammation and
AHR independently of IgE in animal models. Therefore, we
propose that Spred-1 may be a useful therapeutic target to
compensate for atopic and nonatopic asthma.
MATERIALS AND METHODS
Mice. A genomic library from the 129/SV mouse strain (Stratagene) was
screened with a cDNA probe of the mouse Spred-1, and several overlapping
positive clones, including from second to fourth exons, were identified. The
targeting vector was constructed by replacing the fourth exon with a pgk-neo
cassette while preserving 5-Kb (left arm) and 3-Kb (right arm) flanks of ho-
mologous sequences (Fig. 1 A). The hsv-TK gene was inserted for negative
selection. Homologous recombination in murine embryonic stem cells was
performed as described previously (52) and was confirmed by Southern blot
analysis. The chimeric mice were backcrossed to C57BL/6 three times. The
resultant F3 mice were intercrossed to obtain the offspring for analysis. Geno-
mic PCR was performed as described previously (53). The following primer
sets were used: Spred-1 WT, 5 -GCAGACTACAGACATCCGGACAT-
GTGG-3  and 5 -CGCATGGCCCCAATGATACCGGCAAG-3 ; Spred-
1   , 5 -CGAGATCAGCAGCCTCTGTTCCACATAC-3  and 5 -
CCAAGAGAGCTGAGGATGAACTCACCG-3 .
RT-PCR. To detect Spred-1, total RNA was extracted from the bone
marrow, spleen, and brain using TRIzol reagent (GIBCO BRL). RT-PCR
was performed using a GeneAmp RNA PCR kit (PE Biosystems) accord-
ing to the manufacturer’s instructions. The specific primers for Spred-1
were 5 -GATGAGCGAGGAGACGGCGAC-3  and 5 -GTCTCTGA-
GTCTCTCTCCACGGA-3 .
Sensitization and challenge. 10–12-wk-old C57BL/6 mice, Spred-1   
mice, or their WT littermates were sensitized with intraperitoneal injections
of 20  g OVA (Grade V; Sigma-Aldrich) plus 2.25 mg aluminum hydrox-
ide (Pierce Chemical Co.) on days 1 and 14. On days 26–28, mice received
aerosol challenge containing either saline or 1% OVA for 20 min/d.
Measurement of airway responsiveness. On day 30, 36 h after the last
aerosol challenge, mice were ventilated to measure AHR to acetylcholine
aerosol as described previously (22, 54). Airway opening pressure was mea-
sured with a differential pressure transducer and continuously recorded.
Stepwise increases in the acetylcholine dose were given with an ultrasonic
nebulizer. All animal experiments were approved by the Committee on
Animal Research, Faculty of Medicine, Kyushu University. The data were
expressed as the provocative concentration 200 (PC200), the concentration
at which airway pressure was 200% of its baseline value, and PC200 was cal-
culated by log-linear interpolation for individual mice. Lower log PC200
values represent greater AHR. The serum levels of total and OVA-specific
IgE were analyzed by ELISA with rat anti–mouse IgE (Serotec Ltd.).
BAL and cytokine measurements. Mice were exsanguinated with a le-
thal dose of pentobarbital, and their lungs were gently lavaged with 1 ml of
0.9% saline via a tracheal cannula. Total and differential BAL cell counts were
performed as described previously (22). Samples were centrifuged at 2,000
revolutions/min for 10 min, and the supernatants were stored at  80 C.
Mouse IL-4, IL-5, IL-13, and IFN-  were quantified using ELISA kits (Bio-
source International) according to the manufacturer’s protocols. Measure-
ment of cytokine production in BAL fluid was assessed by ELISA assays.
Histological assessment. Lungs were fixed with 10% formalin, and tissue
sections were stained with Alcian blue/PAS to determine the presence of my-
cin glycoconjugates (22). The numerical scores for the abundance of PAS-pos-
itive mucus-containing cells in each airway were determined as follows: 0,
 5% PAS-positive cells; 1, 5–25%; 2, 25–50%; 3, 50–75%; and 4,  75% (36).
Collection of lung cells and lymph node cells. Enzymatic digestion
of the lungs was performed with collagenase type 1A, hyaluronidase, and
DNase, and the samples were filtered through a 52- m nylon mesh. The
erythrocytes were removed by lysis. Cells were stained with FITC-labeled
anti-NK1.1 mAb, PE-labeled anti-CD19 mAb, PerCP-labeled anti-CD3
mAb, and allophycocyanin-labeled anti-CD4 mAb. After flow cytometric
analysis using a FACSCalibur with CellQuest software (BD Biosciences),
the absolute numbers of lung immune cells were calculated. Draining
lymph node cells were collected from paratracheal and mediastinal lymph
nodes, and CD4  T cells isolated with a magnetic cell sorter (Miltenyi Bio-
tec) were stimulated with a combination of 30  g/ml anti-TCR mAb
(H57-597) and 1  g/ml anti-CD28 mAb (PV-1) for 48 h. ELISA assays for
cytokine production were performed as described previously (54).
Cell purification and induction of helper T cells. Naive CD4  T
cells isolated from spleens were stimulated with a combination of anti-TCR
mAb and anti-CD28 mAb, and 10 U/ml rIL-12 and anti–IL-4 mAb
(11B11) were added for Th1 development, while 100 U/ml rIL-4 and anti–
IL-12 mAb (C15.6 and C17.8) were added for Th2 development. ELISA
assays for cytokine production and intracellular cytokine staining were per-
formed as described previously (54).
In vitro colony assay. Single cell suspensions were isolated from the bone
marrow or spleen of WT and Spred-1    mice. The erythrocytes were re-
moved by lysis using NH4Cl and 3   103 cells were plated in methylcellu-
lose (Methocult3434; StemCell Technologies Inc.) containing 10 ng/ml of
IL-5. On day 14, the numbers of colonies were counted microscopically.
Isolation of lung eosinophils. BAL was performed in OVA-sensitized
and -challenged mice by three repeated lavages with RPMI 1640 contain-
ing penicillin-streptomycin at 25 cm H2O. The lavage fluid was collected
and incubated for 30 min to remove macrophages from the cell suspension
by adherence to plastic. Eosinophils were isolated by a negative selection
strategy, removing B cells and T cells with Ab-conjugated magnetic beads
(MACS; Miltenyi Biotec) specific for CD45-R (B220) and CD90 (Thy1.2),
respectively. The purity of the recovered eosinophils was confirmed to be
 98% by staining cytospin preparations with Diff-Quik (neutrophils com-
prise the contaminating cell populations). Eosinophils were cultured at 106
cells/ml for the indicated times.
IL-5 and IL-13 treatment in vivo. Recombinant murine IL-5 (10,000
U/d) was injected intraperitoneally into WT- or Spred-1–deficient mice for
4 d (30). Differential counts were performed by examination of blood
smears stained with a modified Wright-Giemsa stain at various time points.
IL-13 administration was performed as described previously (22). A re-
combinant murine IL-13 solution (0.5 g) or a vehicle solution was instilled
intratracheally on days 1, 3, and 5. BAL was performed on day 6, 24 h after
the last instillation, and BAL cell differentials were determined.
Cell lines and cultures. IL-5–dependent murine cell line, Y16 was cul-
tured in an RPMI 1640 medium containing 5% FBS, 50 mM 2-mercapto-
ethanol, 2 mM L-glutamine, 100 U/ml penicillin G, 100  g/ml streptomy-
cin, and 5 U/ml IL-5 (55). The retrovirus-packaging cell line PLAT-E was
maintained in DMEM containing 10% FBS.
Bone marrow cells from the femoral bone of Spred-1    mice or their
WT littermates were cultured in RPMI 1640 supplemented with 100 U/ml
murine IL-5, 30% FBS, 100 IU/ml penicillin, 100  g/ml streptomycin, and
50  M 2-mercaptoethanol for 2 wk to generate populations of BMEos that
were  95% pure.JEM VOL. 201, January 3, 2005 81
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Chemotaxis assay. The chemotaxis assay was performed in a 96-well dis-
posal chemotaxis plate (5- m pore size; Neuro Probe). In brief, eotaxin was
diluted in RPMI 1640 with 0.1% BSA and placed in the bottom wells (27
 l), 25  l of cell suspension at 4   106 cells/ml was placed on the top well
of the chamber, which was separated from the bottom well by a polycar-
bonate filter. The plate was incubated for 60 min at 37 C in a humidified
incubator with 5% CO2. The cells remaining on top of the filters were ab-
sorbed off, the filter tops were carefully washed, and the plates were centri-
fuged to pellet all cells on the undersides of the filters. The filters were re-
moved, and cells in the bottom wells were counted by light microscopy.
Data are reported as a migration index, calculated as follows: (number of
cells migrating to chemoattractant)/(number of cells migrating to vehicle).
Cell proliferation assay. Cell proliferation was assayed using a Cell
Counting Kit (Dojindo). In brief, 103 Y16 cells were plated in 96-well
plates in RPMI 1640 medium with IL-5 and cultured for 48 h. After adding
WST-8 and 1-methoxy PMS, optical density for 450 nm was measured.
Plasmids, transfection, and infection. WT Spred-1 and COOH-ter-
minal–truncated Spred-1 ( C-Spred-1) were subcloned into pMY-IRES-
GFP vectors for retrovirus infection as described previously (56). In brief,
pMY-IRES-GFP vectors were transfected into a PLAT-E packaging cell
line using the transfection reagent FuGENE 6 (Boehringer) to obtain the
viruses (35). Y16 cells (2   105 cells) were infected with viruses on a Ret-
roNectin (TaKaRa)-coated plate for 24 h in the presence of 5 U/ml IL-5.
Cells were washed three times with PBS, resuspended in RPMI 1640, 5%
FBS containing 5 U/ml IL-5, and incubated for the indicated times. 104
cells were analyzed for GFP fluorescence on a flow cytometer.
Immunochemical analysis. Immunoprecipitation and immunoblotting
were performed using anti-STAT5, anti-ERK2 (Santa Cruz Biotechnology,
Inc.), anti-Flag (M2; Sigma-Aldrich), anti–phospho-TAT5, anti–phospho-
ERK2 (Cell Signaling), and anti–phospho-Ser338-Raf-1 (Upstate Biotech-
nology) antibodies as described previously (56, 57). Anti–Spred-1 antibody
was prepared by immunizing rabbits (17).
Statistical analysis. Values were expressed as the mean   SEM. Differ-
ences among groups were analyzed using unpaired Student’s t tests or an
analysis of variance together with a post-hoc Bonferroni analysis. Nonpara-
metric data were analyzed using the Kruskal-Wallis test followed by the
Mann-Whitney U test. p-values  0.05 were considered to be significant.
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